Aripra10 mg

Aripra is an atypical antipsychotic (a dopamine partial agonist) with the following evidence-based indications:

Established / FDA-Approved Uses

• Schizophrenia - in adults and adolescents 13 years of age and older.
• Bipolar I disorder - treatment of acute manic and mixed episodes, as monotherapy or as an adjunct to lithium or valproate, in adults and pediatric patients 10 years of age and older; also used for maintenance treatment.
• Adjunctive treatment of major depressive disorder (MDD) in adults who have had an inadequate response to antidepressant therapy alone - Aripra is added on to an existing antidepressant, not used as monotherapy for this indication.
• Irritability associated with autistic disorder - in pediatric patients 6 to 17 years of age (symptoms such as aggression, self-injury, and tantrums).
• Tourette's disorder - tic suppression in pediatric patients 6 to 18 years of age.
• Agitation associated with schizophrenia or bipolar I mania - short-acting intramuscular injection formulation, for acute agitation in adults.

Important Note

Aripra is not approved for the treatment of dementia-related psychosis in elderly patients; see Precautions and Warnings for the associated mortality risk in this population.

Each tablet/capsule of Aripiprazole typically contains Aripiprazole as the active pharmaceutical ingredient, commonly available in strengths of 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg (oral tablets and orally disintegrating tablets), as an oral solution (1 mg/mL), and as a short-acting intramuscular injection (9.75 mg/1.3 mL). Strength and formulation available depend on the specific brand and manufacturer.

Aripra is a psychotropic medicine belonging to the atypical (second-generation) antipsychotic class. Unlike older antipsychotics that mainly block dopamine receptors, Aripra acts as a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and as an antagonist at serotonin 5-HT2A receptors. This unique receptor profile allows it to stabilize dopamine and serotonin activity rather than simply blocking it, which is thought to give it a comparatively lower risk of some side effects seen with older antipsychotics, though it carries its own distinct safety profile including akathisia and impulse-control disorders.

Aripra is used mainly in psychiatry for the management of schizophrenia, bipolar I disorder, as an add-on for depression that has not responded fully to standard antidepressants, and for specific pediatric conditions including irritability in autistic disorder and tics in Tourette's disorder.

Atypical (Second-Generation) Antipsychotic - Dopamine Partial Agonist (Aripra)

Mechanism of action: Aripiprazole is believed to exert its therapeutic effects through partial agonism at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, combined with antagonism at serotonin 5-HT2A receptors. This "dopamine system stabilizer" activity functionally dampens dopamine activity in pathways that are overactive (reducing psychotic symptoms) while providing some agonist activity in pathways that are underactive, which may account for its comparatively lower propensity for certain movement side effects at typical doses.

Pharmacokinetics

• Absorption: Well absorbed orally; absolute bioavailability of tablets is approximately 87%. Peak plasma concentrations occur in 3-5 hours.
• Metabolism: Extensively metabolized in the liver mainly via CYP2D6 and CYP3A4 to dehydro-Aripiprazole, an active metabolite with similar receptor affinity.
• Half-life: Approximately 75 hours (Aripiprazole) and 94 hours (dehydro-Aripiprazole) in extensive CYP2D6 metabolizers, allowing once-daily dosing and slow onset/offset of effect.
• Excretion: Primarily via feces, with a smaller portion excreted in urine; negligible amounts excreted unchanged.

Aripra tablets can be taken with or without food, at approximately the same time each day to maintain consistent blood levels. Orally disintegrating tablets should be placed on the tongue and allowed to dissolve without chewing or splitting; they can be taken with or without liquid. The oral solution should be measured using the calibrated dosing device provided. The short-acting intramuscular injection is administered by a healthcare professional only, for acute agitation, and is not for intravenous or subcutaneous use.

Aripra has several clinically significant drug interactions:

• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, quinidine): increase Aripra plasma levels; reduce Aripra dose to about half the usual dose during co-administration.
• CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin): increase Aripra plasma levels; reduce Aripra dose to about half the usual dose during co-administration.
• CYP3A4 inducers (e.g., carbamazepine, rifampin, phenytoin, St. John's Wort): reduce Aripra plasma levels significantly; the Aripra dose should be doubled over 1-2 weeks and reduced again after the inducer is discontinued.
• CNS depressants (alcohol, benzodiazepines, opioids, sedating antihistamines): additive sedation and psychomotor impairment; use with caution and counsel patients to avoid alcohol.
• Antihypertensive agents: Aripra may cause orthostatic hypotension and can add to the blood-pressure-lowering effect of antihypertensive drugs; monitor blood pressure, especially at treatment initiation and dose changes.
• Other antipsychotics/dopaminergic agents: concurrent use is generally avoided due to overlapping effects on the dopamine system unless specifically directed by a physician.

Inform your physician of all medicines, supplements, and herbal products you are taking before starting Aripra.

Side effects of Aripra vary by indication, dose, and patient age. Common and serious effects include:

Common Side Effects

• Akathisia (a feeling of inner restlessness and an inability to sit still) - notably more frequent with Aripra than with many other antipsychotics.
• Headache, insomnia or somnolence/sedation, nausea, vomiting, constipation.
• Anxiety, restlessness, tremor, dizziness, blurred vision.
• Weight gain (generally less pronounced than with some other atypical antipsychotics, but still clinically relevant).

Serious Side Effects (seek prompt medical attention)

• Metabolic changes: hyperglycemia, new-onset or worsening diabetes, and dyslipidemia (elevated cholesterol/triglycerides); periodic monitoring of blood glucose, weight, and lipids is recommended.
• Extrapyramidal symptoms (EPS): muscle stiffness, tremor, abnormal movements.
• Tardive dyskinesia: a potentially irreversible movement disorder that can develop with long-term use; risk increases with duration of treatment.
• Impulse control problems: compulsive or uncontrollable urges to gamble, eat, shop, or engage in sexual behavior have been reported and typically resolve after dose reduction or discontinuation.
• Neuroleptic malignant syndrome (NMS): a rare but life-threatening reaction presenting with high fever, muscle rigidity, altered mental status, and autonomic instability; requires immediate discontinuation and emergency treatment.
• Orthostatic hypotension, syncope, and, rarely, seizures and low white blood cell counts (leukopenia/neutropenia).
• Suicidal thoughts and behavior - see Precautions and Warnings.

Pregnancy: Aripra should be used during pregnancy only if the potential benefit clearly justifies the potential risk to the fetus, and only under close physician supervision. Neonates exposed to antipsychotic drugs, including Aripra, during the third trimester are at risk of extrapyramidal and/or withdrawal symptoms after delivery, such as agitation, abnormal muscle tone, tremor, drowsiness, and feeding difficulty; these symptoms have varied in severity and may require extended hospital monitoring of the newborn. Do not stop or start Aripra during pregnancy without consulting your physician, as untreated psychiatric illness also carries risk.

Lactation: Aripra is excreted in human breast milk. Breastfeeding is generally not recommended during Aripra therapy unless the treating physician determines that the benefits to the mother clearly outweigh the potential risks to the infant, with close monitoring of the infant for sedation, feeding difficulties, and abnormal movements.

Boxed Warnings

• Increased mortality in elderly patients with dementia-related psychosis: elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs, including Aripra, are at increased risk of death compared with placebo, mainly from cardiovascular events or infections such as pneumonia. Aripra is not approved for the treatment of patients with dementia-related psychosis.
• Suicidal thoughts and behaviors: antidepressants and antipsychotics used for depression, including Aripra used as an adjunct, may increase the risk of suicidal thinking and behavior in children, adolescents, and young adults, particularly during the initial months of treatment or after dose changes. Close monitoring for worsening symptoms, agitation, or suicidality is required, especially early in treatment.

Other Warnings

• Impulse control disorders: patients and caregivers should be counseled about the risk of compulsive gambling, eating, shopping, and other impulsive urges; report new or worsening urges to a physician promptly.
• Metabolic effects: monitor for hyperglycemia/diabetes, weight gain, and dyslipidemia periodically during treatment, particularly in patients with pre-existing risk factors.
• Orthostatic hypotension: use with caution in patients with cardiovascular disease, cerebrovascular disease, dehydration, or predisposition to low blood pressure.
• Seizures: use cautiously in patients with a history of seizure disorder or conditions that lower the seizure threshold.
• Cognitive/motor impairment: Aripra may impair judgment, thinking, or motor skills; avoid driving or operating hazardous machinery until the effect of Aripra on the individual is known.
• Body temperature regulation: use caution with strenuous exercise, heat exposure, dehydration, or concomitant medications with anticholinergic activity, as Aripra may impair the body's ability to reduce core temperature.
• Dysphagia (swallowing difficulty): use with caution in patients at risk of aspiration pneumonia.

Symptoms of Aripra overdose may include drowsiness, vomiting, tremor, agitation or aggression, tachycardia, hypotension, confusion, and in severe cases, seizures or loss of consciousness. There is no specific antidote for Aripra overdose.

If an overdose of Aripra is suspected, seek immediate medical attention or contact emergency services/poison control right away. Treatment is supportive and may include cardiac and vital sign monitoring, maintaining an open airway and adequate oxygenation, and symptomatic management in a hospital setting. Do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric Use

Aripra is approved for specific pediatric indications with defined age ranges: schizophrenia (13-17 years), bipolar I disorder manic/mixed episodes (10-17 years), irritability associated with autistic disorder (6-17 years), and Tourette's disorder (6-18 years). Safety and efficacy for other indications, or in children younger than the approved age ranges, have not been established. Dosing in children should always start low and be titrated slowly under specialist supervision.

Elderly (Geriatric) Use

Aripra is not approved for treating dementia-related psychosis in elderly patients due to increased risk of death (see Precautions and Warnings). Elderly patients, particularly those with dementia, should be monitored closely if Aripra is used for an approved indication, with attention to orthostatic hypotension and sedation.

Renal Impairment

No dose adjustment is generally required in patients with renal impairment; clinical experience in severe renal impairment is limited.

Hepatic Impairment

No dose adjustment is generally required in mild-to-moderate hepatic impairment. Use with caution and closer monitoring in severe hepatic impairment.

Duration of Aripra therapy depends on the condition being treated and individual response, and is determined by the prescribing physician. Acute psychotic or manic episodes are typically treated for several weeks before assessing response, while schizophrenia and bipolar disorder often require long-term maintenance therapy to prevent relapse. Do not stop Aripra abruptly without consulting your physician, as this can lead to symptom recurrence or discontinuation effects; any changes in duration or dose should be physician-guided.

Atypical Antipsychotics; Dopamine Partial Agonists (Aripiprazole is a member of this class)

Aripiprazole acts as a partial agonist at dopamine D2 and D3 receptors and at serotonin 5-HT1A receptors, and as an antagonist at serotonin 5-HT2A receptors. By partially stimulating rather than fully blocking or fully activating dopamine receptors, Aripiprazole is thought to stabilize dopaminergic neurotransmission - reducing excess dopamine activity associated with positive psychotic symptoms while providing enough baseline activity to limit effects on pathways responsible for movement and prolactin regulation. This distinctive mechanism differentiates Aripiprazole from both first-generation (typical) antipsychotics and most other second-generation antipsychotics, which act primarily as dopamine receptor antagonists.

C

Aripra has specific pediatric approvals: schizophrenia in adolescents 13-17 years, bipolar I disorder manic/mixed episodes in children and adolescents 10-17 years, irritability associated with autistic disorder in children 6-17 years, and Tourette's disorder in children 6-18 years. Dosing always begins low and is titrated gradually based on response and tolerability under specialist supervision. Safety and efficacy of Aripra have not been established for indications or age groups outside these approved uses. Children and adolescents taking Aripra, particularly for depression-related conditions, must be monitored closely for emergence or worsening of suicidal thoughts, unusual behavior changes, or impulse-control problems.